In less than two years, brand drug companies that now must sell their products to 340B covered entities for a penny due to a history of price increases above inflation may have to start paying entities for their drugs instead of getting paid for them, a biopharma business intelligence firm warns in a new issue brief.
BioCentury analyst Richard Guy describes what could happen starting in 2024 to 340B pricing on Humira, AbbVie’s top-selling immunosuppressive drug, and other brand drugs under language that Congress tucked into a $1.9 trillion COVID-19 relief bill that it passed in March last year.
In less than two years, brand drug companies that now must sell their products to 340B covered entities for a penny due to a history of price increases above inflation may have to start paying entities for their drugs instead of getting paid for them, a biopharma business intelligence firm warns in a new clients-only issue brief.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
